Literature DB >> 11933368

Investigating the bacterial barrier properties of four contemporary wound dressings.

H Ameen1, K Moore, J C Lawrence, K G Harding.   

Abstract

The ability of four wound dressings (CombiDERM, Allevyn Hydrocellular, Tegaderm and Tielle) to resist penetration of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis and Pseudomonas aeruginosa was investigated in vitro using a dedicated test apparatus. With the exception of Tielle, each dressing prevented bacterial transmission over an 11-day challenge period. When both the wound contact surface and the external surface of Tielle were directly challenged with a bacterial suspension, penetration of the dressing was observed within three to five days. The breakdown of its outer membrane could explain the inability of Tielle to maintain a barrier to the passage of the test bacteria used in this wound model. On the basis of these data, CombiDERM, Allevyn Hydrocellular and Tegaderm dressings may facilitate infection control by acting as a physical barrier to the transmission of potentially pathogenic and antibiotic-resistant wound bacteria. However, further research is urgently required to determine whether or not the same results are observed in clinical practice.

Entities:  

Mesh:

Year:  2000        PMID: 11933368     DOI: 10.12968/jowc.2000.9.8.26283

Source DB:  PubMed          Journal:  J Wound Care        ISSN: 0969-0700            Impact factor:   2.072


  3 in total

Review 1.  A dressing history.

Authors:  Douglas Queen; Heather Orsted; Hiromi Sanada; Geoff Sussman
Journal:  Int Wound J       Date:  2004-04       Impact factor: 3.315

Review 2.  National Athletic Trainers' Association Position Statement: Management of Acute Skin Trauma.

Authors:  Joel W Beam; Bernadette Buckley; William R Holcomb; Mario Ciocca
Journal:  J Athl Train       Date:  2017-01-16       Impact factor: 2.860

3.  Topical silver for infected wounds.

Authors:  Joel W Beam
Journal:  J Athl Train       Date:  2009 Sep-Oct       Impact factor: 2.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.